Article 1
Open ↗Didecyldimethylammonium chloride is approved as an active substance for use in biocidal products of product-types 1 and 2 subject to the conditions set out in the Annex.
Commission Implementing Regulation (EU) 2022/1991 of 20 October 2022 approving didecyldimethylammonium chloride as an active substance for use in biocidal products of product-types 1 and 2 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Didecyldimethylammonium chloride is approved as an active substance for use in biocidal products of product-types 1 and 2 subject to the conditions set out in the Annex.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
ANNEX Common Name IUPAC Name Identification Numbers Minimum degree of purity of the active substance ( 1 ) Date of approval Expiry date of approval Product type Specific conditions Didecyldimethylammonium chloride IUPAC name: N,N-Didecyl-N,N-dimethylammonium chloride EC No: 230-525-2 CAS No: 7173-51-5 908 g/kg dry weight 1 February 2024 31 January 2034 1 The authorisation of biocidal products is subject to the following condition: The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. 2 The authorisation of biocidal products is subject to the following conditions: 1. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. 2. The product assessment shall pay particular attention to the exposure and potential risks for professional users. ( 1 ) The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.